Literature DB >> 24681965

PharmGKB summary: very important pharmacogene information for SLC22A1.

Srijib Goswami1, Li Gong, Kathleen Giacomini, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24681965      PMCID： PMC4035531          DOI： 10.1097/FPC.0000000000000048

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  40 in total

1.  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Authors:  M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2009-06-17       Impact factor: 6.875

2.  The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.

Authors:  Mette M H Christensen; Charlotte Brasch-Andersen; Henrik Green; Flemming Nielsen; Per Damkier; Henning Beck-Nielsen; Kim Brosen
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

3.  Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

Authors:  Mladen V Tzvetkov; Joao N dos Santos Pereira; Ingolf Meineke; Ali R Saadatmand; Julia C Stingl; Jürgen Brockmöller
Journal:  Biochem Pharmacol       Date:  2013-07-05       Impact factor: 5.858

4.  Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1).

Authors:  M Hayer; H Bönisch; M Brüss
Journal:  Ann Hum Genet       Date:  1999-11       Impact factor: 1.670

5.  Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors:  Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

6.  Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.

Authors:  Elisa Herraez; Elisa Lozano; Rocio I R Macias; Javier Vaquero; Luis Bujanda; Jesus M Banales; Jose J G Marin; Oscar Briz
Journal:  Hepatology       Date:  2013-07-30       Impact factor: 17.425

7.  Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

Authors:  Brandon Swift; Noelia Nebot; Jin Kyung Lee; Tianxiang Han; William R Proctor; Dhiren R Thakker; Dieter Lang; Martin Radtke; Mark J Gnoth; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-03-12       Impact factor: 3.922

8.  Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma.

Authors:  Wenxian Nie; Seth Sweetser; Mary Rinella; Richard M Green
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-09-30       Impact factor: 4.052

9.  Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1).

Authors:  Moto Kajiwara; Tomohiro Terada; Jun-ichi Asaka; Masayo Aoki; Toshiya Katsura; Iwao Ikai; Ken-ichi Inui
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-09       Impact factor: 4.052

Review 10.  Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.

Authors:  Richard E Clark; Andrea Davies; Munir Pirmohamed; Athina Giannoudis
Journal:  Leuk Lymphoma       Date:  2008-04
View more
  10 in total

Review 1.  Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters.

Authors:  Ji Eun Park; Gongmi Ryoo; Wooin Lee
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

Review 2.  How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.

Authors:  Douglas B Kell; Stephen G Oliver
Journal:  Front Pharmacol       Date:  2014-10-31       Impact factor: 5.810

Review 3.  Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.

Authors:  K Lohitesh; Rajdeep Chowdhury; Sudeshna Mukherjee
Journal:  Cancer Cell Int       Date:  2018-03-20       Impact factor: 5.722

Review 4.  Role of Genetic Variations in the Hepatic Handling of Drugs.

Authors:  Jose J G Marin; Maria A Serrano; Maria J Monte; Anabel Sanchez-Martin; Alvaro G Temprano; Oscar Briz; Marta R Romero
Journal:  Int J Mol Sci       Date:  2020-04-20       Impact factor: 5.923

5.  Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.

Authors:  Thomas J F Angenoorth; Stevan Stankovic; Marco Niello; Marion Holy; Simon D Brandt; Harald H Sitte; Julian Maier
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

6.  The Role of SLC22A1 and Genomic Ancestry on Toxicity during Treatment in Children with Acute Lymphoblastic Leukemia of the Amazon Region.

Authors:  Sweny de S M Fernandes; Luciana P C Leitão; Amanda de N Cohen-Paes; Laura P A Gellen; Lucas F Pastana; Darlen C de Carvalho; Antônio A C Modesto; Ana C A da Costa; Alayde V Wanderley; Carlos H V de Lima; Esdras E B Pereira; Marianne R Fernandes; Rommel M R Burbano; Paulo P de Assumpção; Sidney E B Dos Santos; Ney P C Dos Santos
Journal:  Genes (Basel)       Date:  2022-03-29       Impact factor: 4.141

7.  Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus.

Authors:  Yulia A Nasykhova; Yury A Barbitoff; Ziravard N Tonyan; Maria M Danilova; Ivan A Nevzorov; Tatiana M Komandresova; Anastasiia A Mikhailova; Tatiana V Vasilieva; Olga B Glavnova; Maria I Yarmolinskaya; Evgenia I Sluchanko; Andrey S Glotov
Journal:  Genes (Basel)       Date:  2022-07-23       Impact factor: 4.141

8.  Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus.

Authors:  Ling Li; Ziwan Guan; Rui Li; Wei Zhao; Guoxiang Hao; Yan Yan; Yuedong Xu; Lin Liao; Huanjun Wang; Li Gao; Kunrong Wu; Yuxia Gao; Yan Li
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

9.  SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.

Authors:  Pablo Zubiaur; Maria Dolores Benedicto; Gonzalo Villapalos-García; Marcos Navares-Gómez; Gina Mejía-Abril; Manuel Román; Samuel Martín-Vílchez; Dolores Ochoa; Francisco Abad-Santos
Journal:  J Pers Med       Date:  2021-03-13

Review 10.  Pharmacogenomics and Morphine.

Authors:  Adaku Ofoegbu; Earl B Ettienne
Journal:  J Clin Pharmacol       Date:  2021-06-16       Impact factor: 3.126
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.